Viking Therapeutics stock rises on positive Phase 1 weight-loss pill data

Viking Therapeutics stock rises on positive Phase 1 weight-loss pill data

[ad_1]

Viking Therapeutics (VKTX) reported constructive early part outcomes for its oral weight-loss drug Tuesday, sending the inventory hovering greater than 25% in early buying and selling.

Viking stated its Part 1 outcomes, that are supposed to check the security of the drug, confirmed as much as 5.3% weight reduction in sufferers after 28 days.

The tablet confirmed no questions of safety and a majority of negative effects have been delicate — a key differentiator from present market injectable leaders Novo Nordisk (NVO) and Eli Lilly (LLY).

The outcomes for the oral GLP-1 possibility, which helps sluggish digestion and enhance insulin manufacturing leading to weight reduction, come shortly after Viking reported sturdy weight reduction leads to its injectable model — greater than present market leaders.

“We consider these information point out that longer therapy length, at doubtlessly greater doses, could lead to further weight reduction. We’re significantly happy with the preliminary security and tolerability information, which recommend a differentiated profile with minimal gastrointestinal-related negative effects,” stated CEO Brian Lian in a press release Tuesday.

The corporate will launch the drug into Part 2 trials later this yr.

Leerink Companions analysts known as it a “clear win” for the corporate in a word to traders Tuesday. “We consider these topline information reinforce a best-in-class potential for VK2735,” the word stated.

Final month, the company reported its injectable model of the identical drug resulted in as much as 14.7% weight reduction after 13 weeks of therapy in a Part 2 trial. It has not but introduced particulars of the subsequent step, a bigger Part 3 trial that might show if the outcomes stand as much as the present market competitors.

The drug is ready to compete within the injectable house with Eli Lilly’s Zepbound and Novo Nordisk’s Wegovy. There are presently no market leaders for the oral model.

Anjalee Khemlani is the senior well being reporter at Yahoo Finance, overlaying all issues pharma, insurance coverage, care companies, digital well being, PBMs, and well being coverage and politics. Comply with Anjalee on all social media platforms @AnjKhem.

Click here for in-depth analysis of the latest health industry news and events impacting stock prices

Read the latest financial and business news from Yahoo Finance

administrator

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *